AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- ResMed (RMD) revenue rises with strong global reach
- Netwealth (NWL) scales platform with rising investor activity
- Both stocks showing momentum on the S&P/ASX200 index
Two noteworthy companies listed on the S&P/ASX200 index — ResMed and Netwealth Group are generating investor attention due to recent share price activity and robust financial growth.
ResMed (ASX:RMD): Digital Innovation Meets Global Health
Founded in 1989 in Australia and now headquartered in the US, ResMed has become a leader in digital health and respiratory care. The company’s cloud-enabled CPAP machines, designed to treat obstructive sleep apnea, are supported by a global network that includes over 10,000 employees and operations in 140+ countries.
ResMed’s two core business arms — Sleep and Respiratory Care, and Software as a Service (SaaS) — contribute to its diverse health tech offering. The company’s connected devices not only support therapeutic needs but also drive valuable health data through its SaaS platforms. This integrated digital ecosystem supports patient care outside hospital settings, aligning with modern healthcare trends focused on cost efficiency and better outcomes.
As of FY24, ResMed reported annual revenue of $4.685 billion, up from $2.959 billion in FY21 — reflecting a compound annual growth rate (CAGR) of 13.6%. Net profit more than doubled from $475 million to $1.021 billion in the same period. The company also reported a strong return on equity (ROE) of 22.7%, highlighting efficient capital utilization.
Since the beginning of 2025, ResMed’s share price has increased by 4.4%, showing renewed confidence from market participants.
Netwealth Group (ASX:NWL): Scaling With Digital Wealth Solutions
Netwealth operates a digital platform used by financial planners and individual investors to manage assets efficiently. With over 140,000 active accounts and $88 billion in funds under administration, the company has established a solid footprint in Australia’s wealth-tech landscape.
The firm’s platform enables streamlined investment management, performance tracking, and document access through an intuitive interface — a key strength that enhances user satisfaction and retention.
Financially, Netwealth has grown rapidly. Its revenue rose from $146 million in FY21 to $255 million in FY24, achieving a 20.8% annual growth rate. Net profit also climbed from $54 million to $83 million over the same period, and the company reported an impressive ROE of 62.3%.
Although currently trading 8.4% below its 52-week high, Netwealth’s fundamentals suggest continued traction as digital adoption deepens in wealth management.
Bottom Line
Both ResMed and Netwealth are leveraging their digital capabilities to strengthen business performance. Their inclusion in the S&P/ASX200 index further underscores their significance in the Australian market landscape. As growth trajectories continue, these companies remain actively watched by the broader investment community.
